Targeting ischemia-induced KCC2 hypofunction rescues refractory neonatal seizures and mitigates epileptogenesis in a mouse model.

Abstract

Neonatal seizures pose a clinical challenge in their early detection, acute management, and long-term comorbidities. They are often caused by hypoxic-ischemic encephalopathy and are frequently refractory to the first-line antiseizure medication phenobarbital. One proposed mechanism for phenobarbital inefficacy during neonatal seizures is the reduced abundance and function of the neuron-specific K+/Cl− cotransporter 2 (KCC2), which maintains chloride homeostasis and promotes GABAergic inhibition upon its phosphorylation during postnatal development. Here, we investigated whether this mechanism is causal and whether it can be rescued by KCC2 functional enhancement. In a CD-1 mouse model of refractory ischemic neonatal seizures, treatment with the KCC2 functional enhancer CLP290 rescued phenobarbital efficacy, increased KCC2 abundance, and prevented the development of epileptogenesis, as quantified by video electroencephalogram monitoring. These effects were prevented by knock-in expression of nonphosphorylatable mutants of KCC2 (S940A or T906A and T1007A), indicating that KCC2 phosphorylation regulates both neonatal seizure susceptibility and CLP290-mediated KCC2 functional enhancement. Our findings therefore validate KCC2 as a clinically relevant target for refractory neonatal seizures and provide insights for future drug development.

• Authors: Brennan J Sullivan, Pavel A Kipnis, Brandon M Carter, Li-Rong Shao, Shilpa D Kadam
• Journal: Science signaling (Sci Signal) Vol. 14 Issue 708 Pg. eabg2648 (Nov 09 2021) ISSN: 1937-9145 [Electronic] United States
• PMID: 34752143 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Symporters

Topics

• Animals
• Disease Models, Animal
• Epilepsy (drug therapy)
• Ischemia
• Mice
• Seizures (drug therapy)
• Symporters